Immunotherapy for synovial sarcoma

IF 0.4 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
C. Albert, S. Pollack
{"title":"Immunotherapy for synovial sarcoma","authors":"C. Albert, S. Pollack","doi":"10.3934/MEDSCI.2019.3.191","DOIUrl":null,"url":null,"abstract":"Synovial sarcoma (SS) is a relatively common subtype of soft tissue sarcoma that typically affects young adults. Nearly all tumors harbor a translocation between SS18 and SSX1/SSX2 and the vast majority express the cancer testis antigen (CTA) NY-ESO-1. While patients with small, non-metastatic tumors are often cured surgically, outcomes remain poor for patients with locally advanced or metastatic disease, even when aggressive chemotherapy and radiotherapy are employed. Therefore, innovative systemic therapies that target the biology of the disease are needed to improve outcomes for these higher risk patients. One such category is tumor-directed immune therapies. In this review, we will discuss the current status of immunotherapy for SS, including the recent trial results, ongoing challenges, and future directions.","PeriodicalId":43011,"journal":{"name":"AIMS Medical Science","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2019-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Medical Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/MEDSCI.2019.3.191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 1

Abstract

Synovial sarcoma (SS) is a relatively common subtype of soft tissue sarcoma that typically affects young adults. Nearly all tumors harbor a translocation between SS18 and SSX1/SSX2 and the vast majority express the cancer testis antigen (CTA) NY-ESO-1. While patients with small, non-metastatic tumors are often cured surgically, outcomes remain poor for patients with locally advanced or metastatic disease, even when aggressive chemotherapy and radiotherapy are employed. Therefore, innovative systemic therapies that target the biology of the disease are needed to improve outcomes for these higher risk patients. One such category is tumor-directed immune therapies. In this review, we will discuss the current status of immunotherapy for SS, including the recent trial results, ongoing challenges, and future directions.
滑膜肉瘤的免疫治疗
滑膜肉瘤(SS)是一种相对常见的软组织肉瘤亚型,通常影响年轻人。几乎所有肿瘤都存在SS18和SSX1/SSX2之间的易位,并且绝大多数表达癌睾丸抗原(CTA) NY-ESO-1。虽然小而非转移性肿瘤的患者通常通过手术治愈,但对于局部晚期或转移性疾病的患者,即使采用积极的化疗和放疗,结果仍然很差。因此,需要针对疾病生物学的创新系统疗法来改善这些高风险患者的预后。其中一类是肿瘤导向免疫疗法。在这篇综述中,我们将讨论免疫治疗的现状,包括最近的试验结果,正在进行的挑战和未来的方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
AIMS Medical Science
AIMS Medical Science MEDICINE, RESEARCH & EXPERIMENTAL-
自引率
14.30%
发文量
20
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信